Rocket


News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Xtreme Motorsports International, Inc. (CYAD) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/19/2021 GN Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer
04/01/2021 GN Celyad Oncology Announces April 2021 Conference Schedule
03/31/2021 GN Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
03/18/2021 GN Celyad Oncology to Announce Full Year 2020 Financial Results and Host Conference Call
02/02/2021 GN Celyad Oncology Announces February 2021 Conference Schedule
01/20/2021 GN Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)
01/11/2021 GN Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
01/05/2021 GN Celyad Oncology Announces January 2021 Conference Schedule
12/15/2020 GN Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC
12/07/2020 GN Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
12/04/2020 GN Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma
12/01/2020 GN Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit
11/04/2020 GN Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
09/29/2020 GN Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC
09/23/2020 GN Celyad Oncology to Participate in a Fireside Chat at the 7th Annual Jefferies Cell Therapy Summit
09/22/2020 GN Celyad Oncology to Host Virtual Research & Development Webinar on September 29
09/14/2020 GN Celyad Oncology Establishes At-the-Market Facility
08/26/2020 GN Celyad Oncology Announces September 2020 Conference Schedule
08/03/2020 GN Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call
06/10/2020 GN Celyad Rebrands as Celyad Oncology
06/01/2020 GN Celyad Provides Update on Allogeneic CAR-T Franchise including CYAD-101 and shRNA Platform at the 2020 ASCO Virtual Scientific Program
05/26/2020 GN Celyad Announces June 2020 Conference Schedule
05/07/2020 GN Celyad Announces First Quarter 2020 Financial Results and Recent Business Highlights
04/22/2020 GN Celyad to Host Remote 2020 Ordinary General Meeting
03/24/2020 GN Celyad Reports Full Year 2019 Financial Results and Provides Business Update
03/12/2020 GN Celyad to Announce Full Year 2019 Financial Results and Host Conference Call
03/02/2020 GN Celyad Appoints Stephen Rubino as Chief Business Officer
02/17/2020 GN Celyad Announces February and March 2020 Conference Schedule
01/13/2020 GN Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
12/06/2019 GN Celyad Receives Additional €2.5 Million in Non-Dilutive Funding
11/29/2019 GN Celyad Announces Board of Directors Evolution with New Appointment
11/22/2019 GN Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region
11/19/2019 GN Celyad Announces Third Quarter 2019 Financial Results and Recent Business Highlights
11/11/2019 GN Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy